In conclusion, our study found and confirmed that Nesfatin-1 could improve both glucose metabolism disorders and diabetic Ed in T2DMED mice, and this effect may be mediated by Nesfatin-1 promoting the transformation of corpus cavernosus smooth muscle cells to contractile phenotype through the PI3K/AKT/mTOR signaling pathway. This evidence concerns the gene MTOR and glucose metabolism disease.